ARGX vs IONS
argenx SE vs Ionis Pharmaceuticals, Inc. — AI-powered side-by-side comparison
VS
IONS
Ionis Pharmaceuticals, Inc.
43
Reduce
| Metric | ARGX | IONS |
|---|
| AI Score |
69
|
43
|
| Price |
$864.40
|
$55.38
|
| P/E Ratio |
31.34×
|
-16.02×
|
| ROE |
17.6%
|
-77.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.9%
|
98.2%
|
| Debt / Equity |
0.01×
|
5.50×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
47.9
|
46.6
|
| Beta |
-0.022
|
0.4
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ARGX versus IONS.
ARGX leads by 26 points.
ARGX scores 69/100 (Buy) versus IONS at 43/100 (Reduce).
ARGX Committee View
67% agreement
6 analysts
The primary driver is revenue growing 71.3% yoy -- genuine top-line momentum. The main limiting factor is price-to-book of 6.9x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 22.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
- EPS growing 95.7% YoY — Growth
Bear Case
- Price-to-book of 6.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
IONS Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -7.5% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 26.2x prices in significant intangible value — Value
- ROE of only -110.9% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 4.77 adds balance-sheet risk to the value case — Value